



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

05.08.2020

To,
Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome Of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Wednesday 05th August, 2020, at TU-40 Pitampura, Delhi-110034**, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter ended 30th June, 2020.
2. Appointment of PKG & Associates as a Scrutinizer for process of e-voting in the 28th Annual General Meeting of the Company.

In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:


1. Unaudited Financial Results for the quarter ended 30th June, 2020.
2. Limited Review Report for the quarter ended 30th June, 2020.

The meeting of Board of Directors commenced at 04:00 P.M. and concluded at 04:30 P.M.

The above information will be available on the website of the company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking you,
Yours faithfully,
For Titan Biotech Limited


Charanjit Singh
Company Secretary
Membership Number: A12726

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: marketing@titanbiotechltd.com


Website: www.titanbiotechltd.com | www.titanmedia.in



To the Board of Directors of TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of TITAN BIOTECH LIMITED (the "Company") for the quarter/ three months ended 30th June, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulation") as amended, read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 (the "Circular").
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co
Chartered Accountants
ICAI FRN- 515225C


(CA Sunita Agrawal)
Partner

Membership No.095196
UDIN-20095196AAAAFR7435



Delhi, Aug 5, 2020



Independent Auditor's Limited Review Report

To the Board of Directors of TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **TITAN BIOTECH LIMITED** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the Quarter/ three months ended **30th June, 2020** ("the Statement") being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to group financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes results of the Holding Company- Titan Biotech Limited and subsidiary Company - Peptech Biosciences Limited.
5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.
6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Sunita Agrawal & Co**
Chartered Accountants
ICAI FRN- 515225C


(CA Sunita Agrawal)

Partner

Membership No.095196

UDIN-20095196AAAAFS1648



Delhi, Aug 5, 2020

Head Office : 10, Giriraj Nagar, Inside Fort, Bharatpur (Rajasthan)-321001, Ph. : 05644-225679, M : 9899567391
Branch Office : A-160, Boulevard, Hotel Crowne Plaza, Mayur Vihar, Phase-1, Delhi-110091, Ph. : 011-49868379

E-mail : sunitaca_97@yahoo.com || sac.icai@gmail.com | info@taxfirst.in

Web : www.consultants.tax, www.taxfirst.in

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE			
		QUARTER ENDED			YEAR ENDED
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	INCOME				
	Revenue from operations	3490.93	1,800.55	1,746.33	6,947.63
	Other Income	20.09	21.00	9.05	40.95
	Total Income	3,511.02	1,821.55	1,755.38	6,988.58
2	EXPENSES				
	Cost of Materials Consumed	1257.01	859.47	993.56	3,674.27
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(73.30)	(20.43)	11.70	(65.44)
	Employee Benefit Expenses	249.69	292.11	223.37	1,002.60
	Finance Costs	24.86	48.15	51.11	190.09
	Depreciation and Amortization Expenses	43.79	43.30	43.20	174.52
	Other Expenses	388.54	366.12	262.11	1,249.70
	Total Expenses	1,890.59	1,588.72	1,585.05	6,225.74
3	Profit/(loss) before exceptional items and tax (1-2)	1,620.43	232.83	170.33	762.84
4	Exceptional Items	9.00	0.00	-	61.41
5	Profit/ (loss) before tax (3+4)	1,629.43	232.83	170.33	824.25
6	Tax expense:				
	I) Current Tax	404.56	44.97	39.85	184.84
	II) Deferred Tax	5.53	(5.39)	7.54	19.27
	Total Tax (I+II)	410.09	39.58	47.39	204.11
7	Profit (Loss) for the period after Tax (5-6)	1,219.34	193.25	122.94	620.14
8	Other comprehensive income (Net of Tax)				
A.	Items that will not be reclassified to profit or loss			-	
	Re-measurement gain on defined benefit plans	-	(4.71)	-	(4.71)
	(i) Items that will be reclassified to profit or loss		-	-	
B	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	
	Total Other Comprehensive Income for the period (A+B)(net of taxes)	-	(4.71)	-	(4.71)
9	Total Comprehensive Income for the period (7+8)	1,219.34	188.54	122.94	615.43
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37
11	Other Equity			-	2,954.96
12	Earnings per equity share (face value of Rs.10/- each) not annualised				
	(1) Basic	14.76	2.34	1.49	7.50
	(2) Diluted	14.76	2.34	1.49	7.50

Notes:

- The above unaudited standalone financial results for the quarter ended 30.06.2020 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 05,2020.The above result have been audited by Statutory Auditors of the Company in terms of Regulation 33 of the SEBI(Listing Obligation and Disclosure Requirments), 2015
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019.Accordingly, the Company has recognized provision for income tax for the quarter ended on 30 June 2020 and remeasured ist deferred tax balance on the basis of the rate prescribed in the said section.
- The exceptional sharp rise in the revenue of company during the quarter ended 30.06.2020 was mainly due to supply of products the need for which arose due to COVID-19 pandemic.**
- The COVID-19 outbreak and resulted national lockdown imposed by the Government of India has caused Pan-India disruption of business for products covered under non essential category. The company has considered the possible risk that may result from the pandemic on the carrying amount of its financial and non-financial assets, for which the Company has used the principles of prudence in applying judgments and assumptions as well as the internal / external information available up to the date of approval of these results and the same does not have material impact on these financial results. The Company will continue to closely monitor any material impact of future economic conditions.
- The extraordinary income (Export Incentive) Rs. 900874.00 has been shown in exceptional items.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors
For TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director

Place : Delhi

Dated : 05.08.2020

DIN-00027448

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE			
		QUARTER ENDED		YEAR ENDED	
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	3,511.02	1,821.55	1,755.38	6,988.58
2	Net Profit/(Loss) for the period (before tax,exceptional and/or extraordinary items)	1,620.43	232.83	170.33	762.84
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	1,629.43	232.83	170.33	824.25
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	1,219.34	193.25	122.94	620.14
5	Total comprehensive income for the period (comprising Profit/(Loss)for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	1,219.34	188.54	122.94	615.43
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	2,954.96
8	Earning Per Share (of INR 10/- each)				
	(a) Basic	14.76	2.34	1.49	7.50
	(b) Diluted	14.76	2.34	1.49	7.50

NOTES :

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter ended 30.06.2020 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter ended 30.06.2020 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above unaudited standalone financial results for the quarter ended 30.06.2020 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 05,2020.The above result have been audited by Statutory Auditors of the Company in terms of Regulation 33 of the SEBI(Listing Obligation and Disclosure Requirments), 2015
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019.Accordingly, the Compay has recognized provision for income tax for the quarter ended on 30 June 2020 and remeasured ist deferred tax balance on the basis of the rate prescribed in the said section.
- The exceptional sharp rise in the revenue of company during the quarter ended 30.06.2020 was mainly due to supply of products the need for which arose due to COVID-19 pandemic.**
- The COVID-19 outbreak and resulted national lockdown imposed by the Government of India has caused Pan-India disruption of business for products covered under non essential category. The company has considered the possible risk that may result from the pandemic on the carrying amount of its financial and non-financial assets, for which the Company has used the principles of prudence in applying judgments and assumptions as well as the internal / external information available up to the date of approval of these results and the same does not have material impact on these financial results. The Company will continue to closely monitor any material impact of future economic conditions.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards (‘Ind AS’) specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the “accounting principles generally accepted in India”).

For and on behalf of Board of Directors
For TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director

Place : Delhi

Dated : 05.08.2020

DIN-00027448

TITAN BIOTECH LIMITED
Standalone Balance Sheet as at 30th June, 2020

(Rs. in Lakhs.)

Particulars	As at	
	30/06/2020	31/03/2020
	Unaudited	Audited
<u>I ASSETS</u>		
1. Non-Current Assets		
a. Property, Plant and Equipment	2,553.31	2,513.80
b. Capital Work-in-Progress	-	-
c. Intangible assets	10.09	10.09
d. Financial Assets	-	-
(i) Investments	127.50	127.50
(ii) Other Financial Assets	126.69	57.62
Total Non-current assets	2,817.59	2,709.01
2. Current Assets		
a. Inventories	2,692.75	2,414.03
b. Financial Assets	-	-
(i) Trade receivables	1,505.37	1,053.92
(ii) Cash and cash equivalents	623.32	170.10
(iii) Bank balances other than (ii) above	30.45	2.46
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	460.20	170.34
Total Current assets	5,312.09	3,810.85
TOTAL ASSETS	8,129.68	6,519.86
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	4,174.31	2,954.97
TOTAL EQUITY	5,000.68	3,781.34
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	1,138.81	847.82
b. Deferred tax liabilities (Net)	125.21	119.67
c. Provisions	123.91	123.91
Total Non-Current Liabilities	1,387.93	1,091.40
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	646.11	840.97
(ii) Trade payables	317.31	357.03
(iii) Other financial liabilities	303.81	283.14
b. Other current liabilities	94.31	127.01
c. Current Tax Liabilities (Net)	379.53	38.97
Total Current Liabilities	1,741.07	1,647.12
TOTAL EQUITY AND LIABILITIES	8,129.68	6,519.86

For and on behalf of Board of Directors
For TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director

Place : Delhi

Date : 05.08.2020

DIN-00027448

TITAN BIOTECH LIMITED

Standalone Cash Flow Statement for the period ended 30th June, 2020

(Rs. in Lakhs.)

Particulars	As at	
	30/06/2020 Audited	31/03/2020 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	1,629.44	824.25
Adjustment for :	-	-
Finance Costs	24.86	190.09
Provisions	-	21.72
Depreciation and Amortization Expenses	43.79	174.52
Operating profit before working capital changes	1,698.09	1,210.58
Changes in working Capital:		
Inventories	(278.72)	(418.02)
Trade and other Receivables	(810.38)	(189.16)
Trade and other Payables	(51.75)	242.78
Cash generation from Operation	557.24	846.18
Payment of Direct Taxes	(63.99)	(153.86)
Net Cash generated/ (used) - Operating Activities	493.25	692.32
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Fixed Assets (incl.Capital WIP)	(83.30)	(108.00)
Proceeds/ Repayment of Loans to Body Corporate (Net)	-	-
Movement in Fixed Deposits with Banks	(28.00)	13.67
Net Cash Generated/ (Used) - Investing Activities	(111.30)	(94.33)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	290.99	(353.79)
Proceeds/(Repayment) of Short-term Borrowings (Net)	(194.86)	(42.81)
Proceeds from Issue of Share Capital	-	-
Finance Cost paid	(24.86)	(190.09)
Dividend paid (including Dividend Distribution Tax)	-	-
Net Cash Generated/ (Used) - Financing Activities	71.27	(586.69)
Net Increase/ (Decrease) in Cash and Cash Equivalents	453.22	11.30
Add : Opening Cash and Cash Equivalents	170.10	158.80
Closing Cash and Cash Equivalents (refer note-8)	623.32	170.10

Notes:

1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting
2. Figures in bracket represent outflows.
3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For and on behalf of Board of Directors
For TITAN BIOTECH LIMITED




NARESH KUMAR SINGLA
Managing Director

Place : Delhi

Date : 05.08.2020

DIN-00027448

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
	UNAUDITED	AUDITED	UNAUDITED	AUDITED	
1	INCOME				
	Revenue from operations	3941.86	2,007.84	2,209.37	7,943.80
	Other Income	23.36	18.18	11.16	44.95
	Total Income	3,965.22	2,026.02	2,220.54	7,988.75
2	EXPENSES				
	Cost of Materials Consumed	1481.12	953.62	1,169.82	4,024.07
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(67.33)	(38.30)	10.82	(89.24)
	Employee Benefit Expenses	294.19	348.85	277.72	1,247.49
	Finance Costs	37.11	61.20	60.08	233.58
	Depreciation and Amortization Expenses	45.25	44.95	44.39	180.02
	Other Expenses	416.48	427.20	297.87	1,413.82
	Total Expenses	2,206.82	1,797.52	1,860.70	7,009.74
3	Profit/(loss) before exceptional items and tax (1-2)	1,758.40	228.50	359.84	979.01
4	Exceptional Items	9.00	0.00	-	61.41
5	Profit/ (loss) before tax (3+4)	1,767.40	228.50	359.84	1,040.42
6	Tax expense:				
	I) Current Tax	439.51	39.12	92.21	239.38
	II) Earlier year taxes	-	(2.39)	-	(2.39)
	III) Deferred Tax	5.76	(3.19)	7.90	19.69
	Total Tax (I+II)	445.27	33.54	100.11	256.68
7	Profit (Loss) for the period after Tax (5-6)	1,322.13	194.95	259.73	783.74
8	other comprehensive income (Net of Tax)				
	Items that will not be reclassified to profit or loss		-	-	-
A.	Re-measurement gain on defined benefit plans	-	(5.02)	-	(5.02)
	(i) Items that will be reclassified to profit or loss		-	-	-
B	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-
	Total Other Comprehensive Income for the period (A+B)(net of taxes)	-	(5.02)	-	(5.02)
9	Total Comprehensive Income for the period (7+8)	1,322.13	189.93	259.73	778.72
10	Net profit attributable to:				
	Owners of the holding company	1273.94	192.47	195.61	706.58
	Non-controlling interest	48.19	2.49	64.12	77.16
11	Other comprehensive income attributable to :				
	Owners of the holding company	-	(4.88)	-	(4.88)
	Non-controlling interest	-	(0.14)	-	(0.14)
12	Total Comprehensive Income attributable to (10+11)				
	Owners of the holding company	1,273.94	187.59	195.61	701.70
	Non-controlling interest	48.19	2.35	64.12	77.02
13	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37
14	Other Equity				
				-	3,092.96
15	Earnings per equity share (face value of Rs.10/- each) not annualised				
	(1) Basic	15.42	2.33	2.37	8.55
	(2) Diluted	15.42	2.33	2.37	8.55

Notes:

- The above consolidated unaudited financial results for the quarter ended 30.06.2020 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 05, 2020. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The consolidated audited financial results for the quarter and year ended 30.06.2020 include the results of following:-
Subsidiary Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30 June 2020 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The exceptional sharp rise in the revenue of company during the quarter ended 30.06.2020 was mainly due to supply of products the need for which arose due to COVID-19 pandemic.**
- The exceptional sharp rise in the revenue of company during the quarter ended 30.06.2020 was mainly due to supply of products the need for which arose due to COVID-19. The COVID-19 outbreak and resulted national lockdown imposed by the Government of India has caused Pan-India disruption of business for products covered under non essential category. The company has considered the possible risk that may result from the pandemic on the carrying amount of its financial and non-financial assets, for which the Company has used the principles of prudence in applying judgments and assumptions as well as the internal / external information available up to the date of approval of these results and the same does not have material impact on these financial results. The Company will continue to closely monitor any material impact of future economic conditions.
- Previous period figures are regrouped/reclassified in line with the current period.
- The extraordinary income (Export Incentive) Rs. 900874.00 has been shown in exceptional items.
- The Company has only one reportable business segment.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors
For TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director

Place : Delhi

Dated :05.08.2020

DIN-00027448

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

S.NO.	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED			YEAR ENDED
		30.06.2020	31.03.2019	30.06.2019	31.03.2020
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	3,965.22	2,026.02	2,220.54	7,988.75
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	1,758.40	228.50	359.84	979.01
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	1,767.40	228.50	359.84	1,040.42
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	1,322.13	194.95	259.73	783.74
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	1,322.13	189.93	259.73	778.72
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	3,092.96
8	Earning Per Share (of INR 10/- each)				
	(a) Basic	15.42	2.33	2.37	8.55
	(b) Diluted	15.42	2.33	2.37	8.55

NOTES :

- The above is an extract of the detailed format of consolidated audited Financial Results for the quarter ended 30.06.2020 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter ended 30th June, 2020 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter ended 30.06.2020 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 05, 2020. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31 March 2020 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section..
- The exceptional sharp rise in the revenue of company during the quarter ended 30.06.2020 was mainly due to supply of products the need for which arose due to COVID-19 pandemic.**
- The exceptional sharp rise in the revenue of company during the quarter ended 30.06.2020 was mainly due to supply of products the need for which arose due to COVID-19. The COVID-19 outbreak and resulted national lockdown imposed by the Government of India has caused Pan-India disruption of business for products covered under non essential category. The company has considered the possible risk that may result from the pandemic on the carrying amount of its financial and non-financial assets, for which the Company has used the principles of prudence in applying judgments and assumptions as well as the internal / external information available up to the date of approval of these results and the same does not have material impact on these financial results. The Company will continue to closely monitor any material impact of future economic conditions.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors
For TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director

Place : Delhi

Dated : 05.08.2020

DIN-00027448

TITAN BIOTECH LIMITED
Consolidated Balance Sheet as at 30th June, 2020

(Rs. in Lakhs.)

Particulars	As at	
	30/06/2020 Unaudited	31/03/2020 Audited
I ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	3,145.80	3,106.25
b. Capital Work-in-Progress	6.60	6.60
c. Intangible assets	10.09	10.09
d. Financial Assets	-	-
(i) Other Financial Assets	130.00	60.93
e. Other Non Current Assets	0.30	0.30
Total Non-current assets	3,292.79	3,184.17
2. Current Assets		
a. Inventories	3,105.37	2,797.58
b. Financial Assets	-	-
(i) Trade receivables	1,769.98	1,186.25
(ii) Cash and cash equivalents	696.34	183.27
(iii) Bank balances other than (ii) above	30.46	2.46
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	507.49	250.23
Total Current assets	6,109.64	4,419.79
TOTAL ASSETS	9,402.43	7,603.96
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	4,366.90	3,092.96
c. Non Controlling Interest	283.36	235.17
TOTAL EQUITY	5,476.63	4,154.50
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	1,488.29	1,155.38
b. Deferred tax liabilities (Net)	129.03	123.27
c. Provisions	127.84	127.83
Total Non-Current Liabilities	1,745.16	1,406.48
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	807.81	1,134.05
(ii) Trade payables	504.28	412.39
(iii) Other Financial Liabilities	348.34	322.99
b. Other current liabilities	110.72	135.05
c. Current Tax Liabilities (Net)	409.49	38.50
Total Current Liabilities	2,180.64	2,042.98
TOTAL EQUITY AND LIABILITIES	9,402.43	7,603.96

For and on behalf of Board of Directors
For TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director

Place : Delhi
Date : 05.08.2020

DIN-00027448

TITAN BIOTECH LIMITED
Consolidated Cash Flow Statement for the period ended 30th June, 2020
(Rs. in Lakhs.)

Particulars	As at	
	30/06/2020 Unaudited	31/03/2020 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	1,767.40	1,040.42
Adjustment for :	-	-
Finance Costs	37.11	233.58
MAT Credit	-	2.65
Earlier year Taxes	-	(0.26)
Provision for employees Benefits	-	23.55
Depreciation and Amortization Expenses	45.25	180.02
Unamortized Expenses	-	0.30
Operating profit before working capital changes	1,849.76	1,480.26
Changes in working Capital:		
Inventories	(307.80)	(684.26)
Trade and other Receivables	(910.05)	(243.77)
Trade and other Payables	92.92	278.11
Cash generation from Operation	724.83	830.34
Payment of Direct Taxes	(68.53)	(218.70)
Net Cash generated/ (used) - Operating Activities	656.30	611.64
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Fixed Assets (incl.Capital WIP)	(84.80)	(401.14)
Proceeds/ Repayment of Loans to Body Corporate (Net)	(326.24)	166.43
Movement in Fixed Deposits with Banks	(28.00)	13.67
Net Cash Generated/ (Used) - Investing Activities	(439.04)	(221.04)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	332.92	(161.23)
Proceeds from Issue of Share Capital	-	-
Finance Cost paid	(37.11)	(233.58)
Dividend paid (including Dividend Distribution Tax)	-	-
Net Cash Generated/ (Used) - Financing Activities	295.81	(394.81)
Net Increase/ (Decrease) in Cash and Cash Equivalents	513.07	(4.21)
Add : Opening Cash and Cash Equivalents	183.27	187.48
Closing Cash and Cash Equivalents	696.34	183.27

Notes:

1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting
2. Figures in bracket represent outflows.
3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For and on behalf of Board of Directors
For TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director

Place : Delhi
Date : 05.08.2020

DIN-00027448